COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

Low Cell Input? No Problem! CPTAC Researchers Develop Low Sample Input Proteomics Protocol

Proteomic profiling often entails using a large sample input to explore the dynamic nature of protein expression and regulation. However, there are instances when researchers have the opposite due to prior methodology such as fluorescence activated cell sorting (FACS) or when dealing with patient samples.


Amsterdam UMC Joins the ICPC

June 13th, 2019 marked the addition of our 33rd institution to the International Cancer Proteogenomic Consortium (ICPC).  We are pleased to include Amsterdam UMC as a participant in the global effort to accelerate cancer research.


The National Cancer Center - Korea (NCC-K) Joins the International Cancer Proteogenomic Consortium (ICPC)

The National Cancer Center - Korea (NCC-K) joins the International Cancer Proteogenome Consortium (ICPC) global partnership.  The NCC-K has joined the ranks of 31 institutions in 12 countries around the world that have previously made this commitment with the


Proteomic Dataset Release of the CPTAC and CBTTC Collaborative Pediatric Brain Tumor Pilot Study

While it’s a common misconception that all tumors in the brain are the same, there are more than 120 subtypes of brain cancers with very diverse features and diagnosis.


Dr. Rodriguez Speaks at JSN, Fujita, and Nagoya University about the Power of Proteogenomics

Dr. Henry Rodriguez gave the keynote address at the 62nd Annual Meeting of the Japanese Society of Nephrology in Nagoya, Japan this week.  In line with the conference’s theme Open The Future, Dr.


The Magic of Proteogenomics Explained Series: CPTAC Proteogenomics Program

Since its first mention in the scientific literature in 2004 by Jaffe et al1, the term proteogenomics has been shrouded in mystery and thick technical language.  It is a complex idea, but one that is gaining traction as its value to improve our understanding of cancer development and potentially guide novel treatment strategies is being uncovered.


CPTAC Develops a New Technique (BASIL) to Enhance Phospho Sensitivity from a Small Population of Cells (feasibility on human pancreatic islets)

Phosphorylation is a key process in the regulation of protein activity and has long been appreciated as an essential mechanism for the control of cellular function - tells a protein where to go, what to bind to and even when to die.


CPTAC Releases Lung Adenocarcinoma (LUAD) Proteomic Dataset

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to release its newest comprehensive dataset - deep proteomic/phosphoproteomic data and imaging data of Lung Adenocarcinoma (LUAD) patient tumors.  The CPTAC Tumor Characterization Program uses proteogenomic analysis to systematically identify proteins that derive from alterations in cancer genomes and related biological processes and provide this data with accompanying assays, reagents and protocols to the public that allows a wider group of scientists to extend and accelerate knowledge in unanticipated directions.

...


Congratulations to the Best Performers of the precisionFDA/NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Correction Big Data Challenge

Riding the wave of the future requires scientists to move away from silo-thinking to an inclusive and collaborative mind set. By leveraging the power of crowdsourcing, precisionFDA and NCI-CPTAC teamed up to launch the Multi-omics Enabled Sample Mislabeling Correction Big Data Challenge. Over 500 participants from 20 countries joined the call to develop computational algorithms that would identify multi-omics samples that were switched prior to or during data processing and analysis. By looking at genomic, transcriptomic and proteomic datasets mined from a several single-subject cases,...


CPTAC Researchers Analyze Colon Cancer Proteins and Genes to Uncover New Potential Treatments

Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.


Pages